Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin

被引:61
|
作者
Gupta, CK
Leszczynski, J
Gupta, RK
Siber, GR
机构
[1] Chiron Vaccines, Mailstop Q101, Emeryville, CA 94608
关键词
respiratory syncytial virus; defective interfering particles; stabilizers;
D O I
10.1016/S0264-410X(96)00096-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A high-titered and stable respiratory syncytial virus (RSV) is essential for the development of RSV vaccines and quality control of vaccines and RSV immune globulin. We increased the virus titer of RSV seed stock, and virus preparations made from this seed stock, 100 times by removing defective interfering particles using limiting dilution procedure. RSV preparations made from the new seed stock had infectivity titers ranging from 10(7.6) to 10(8.2) TCID50 per ml for five lots made over a period of 3 years. Unstabilized RSV lost most of its infectivity at -86 degrees C within 2-3 weeks, at 37 degrees C within 24 hr, at 56 degrees C within 3 min and after five freeze-thaw cycles. The high titered virus was stabilized at -86 degrees C for 3 years, at 37 degrees C for 3 days, at 56 degrees C for 6 min and against five freeze-thaw cycles. Most effective stabilizers included 25% sucrose, 10% trehalose and 45% fetal bovine serum (FBS) in Medium 199 whereas 3.5% dimethyl sulfoxide, greater than or equal to 45% FBS in phosphate buffered saline, 40% glycerol and 10% sorbitol also stabilized RSV to lesser and variable degrees. A mixture of 0.5% gelatine and 0.3% sodium glutamate stabilized the vir us for a short period whereas 0.1 M MgCl2 and 25% FBS did not stabilize the virus. The stabilized high-titered virus is very useful for achieving reproducibility in serologic assays. A broad spectrum of stabilizers, such as those evaluated in this study, would be useful in choosing the most suitable formulation for stabilizing a live RSV vaccine. Copyright (C) 1996 Elsevier Science Ltd.
引用
收藏
页码:1417 / 1420
页数:4
相关论文
共 31 条
  • [1] Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin (vol 14, pg 1417, 1996)
    Gupta, CK
    Leszczynski, J
    Gupta, RK
    Siber, G
    [J]. VACCINE, 1997, 15 (02) : R3 - R3
  • [2] Development of mRNA vaccines against respiratory syncytial virus (RSV)
    Qiu, Xirui
    Xu, Siyan
    Lu, Yang
    Luo, Zichen
    Yan, Yangtian
    Wang, Chuyue
    Ji, Jianjian
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2022, 68 : 37 - 53
  • [3] Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection
    Robinson, RF
    Nahata, MC
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (03) : 259 - 264
  • [4] Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab
    Canfield, SD
    Simoes, EAF
    [J]. PEDIATRIC ANNALS, 1999, 28 (08): : 507 - +
  • [5] Development of respiratory syncytial virus (RSV) vaccines for infants
    Gerretsen, Hannah E.
    Sande, Charles J.
    [J]. JOURNAL OF INFECTION, 2017, 74 : S143 - S146
  • [6] TOPICAL IMMUNOPROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS (RSV)-CHALLENGED MICE WITH RSV-SPECIFIC IMMUNE GLOBULIN
    GRAHAM, BS
    TANG, YW
    GRUBER, WC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (06): : 1468 - 1474
  • [7] RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN PRETERM INFANTS AND THE PROTECTIVE EFFECTS OF RSV IMMUNE GLOBULIN (RSVIG)
    GROOTHUIS, JR
    SIMOES, EAF
    HEMMING, VG
    LEVIN, MJ
    SONDHEIMER, H
    LEHR, MV
    LOUCH, GK
    HALL, CB
    POWELL, KR
    LONG, CE
    PINCUS, PR
    SCHNABEL, KC
    RODRIGUEZ, WJ
    ARROBIO, J
    KIM, HW
    PARROTT, RH
    FINK, R
    RUCKMAN, R
    REVENIS, M
    CHANEY, H
    PIAZZA, F
    MEISSNER, HC
    FULTON, DR
    MARX, GR
    GEGGEL, RL
    WELLIVER, RC
    TRISTRAM, DA
    SIBER, GR
    LESZCZYNSKI, J
    MCIVER, J
    HENSEN, SA
    VINCENT, MM
    [J]. PEDIATRICS, 1995, 95 (04) : 463 - 467
  • [8] Current approaches to the development of vaccines against RSV [Aktuelle ansatze zur impfstoffentwicklung gegen respiratory-syncytial-virus (RSV)]
    Weitkamp J.H.
    Crowe J.E.
    [J]. Monatsschrift Kinderheilkunde, 2000, 148 (11) : 980 - 989
  • [9] Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection (vol 57, pg 259, 2000)
    Robinson, RF
    Nahata, MC
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (07) : 699 - 699
  • [10] Immune Profiling of Respiratory Syncytial Virus (RSV) for the Development of Targeted Immunotherapy
    Papayanni, Penelope Georgia
    Koukoulias, Kiriakos
    Kuvalekar, Manik
    Watanabe, Ayumi
    Velazquez, Yovana
    Ramos, Carlos A.
    Leen, Ann M.
    Vasileiou, Spyridoula
    [J]. MOLECULAR THERAPY, 2023, 31 (04) : 162 - 162